Postpartum Low Mood: Labs, Causes, and Your Next Steps

What is postpartum low mood, and why does it happen?

Postpartum low mood is not a single diagnosis. It is a spectrum of mood changes that can start within hours of delivery and, for some women, persist for months. The causes range from the steepest hormonal drop of your entire life to treatable medical conditions that go undetected because providers sometimes assume sadness after birth is "just hormonal."

After you deliver the placenta, your estrogen and progesterone levels fall by roughly 100-fold within 72 hours. That drop is faster and larger than anything that happens during the menstrual cycle or even perimenopause. Your brain's serotonin and dopamine systems are directly sensitive to estrogen; the withdrawal is real and measurable.

At the same time, your cortisol, oxytocin, and prolactin (if you are breastfeeding) are all shifting. Sleep deprivation compounds every biological signal. You are not imagining it. Your brain chemistry has genuinely changed.

The hormonal cascade after delivery

The placenta produces large amounts of progesterone and estrogen throughout pregnancy. Delivery removes that source almost instantly. Women who go on to develop postpartum depression show heightened neurobiological sensitivity to this hormonal withdrawal, not simply a larger drop, which may explain why some women are more vulnerable than others.

Allopregnanolone, a progesterone metabolite that acts on GABA receptors (the same receptors targeted by benzodiazepines), also collapses postpartum. This is directly why brexanolone (Zulresso), a synthetic allopregnanolone, became the first FDA-approved treatment specifically for postpartum depression in 2019.

Non-hormonal contributors you should not overlook

Mood after birth is shaped by more than estrogen. Four other factors frequently drive or worsen low mood:

• Iron deficiency. Blood loss during delivery can be substantial. Ferritin below 30 ng/mL is associated with fatigue, cognitive slowing, and depressed mood, and is often missed because hemoglobin can look normal even when iron stores are depleted. One prospective study found that iron-deficient postpartum women had significantly higher Edinburgh Postnatal Depression Scale scores.
• Thyroid dysfunction. Postpartum thyroiditis affects 5-10% of postpartum women and is frequently misattributed to normal postpartum fatigue. It has two phases: a hyperthyroid phase at 1-4 months (anxiety, palpitations, insomnia) followed by a hypothyroid phase at 4-8 months (fatigue, weight gain, low mood). Women with pre-existing thyroid antibodies or type 1 diabetes carry the highest risk.
• Vitamin D deficiency. Low vitamin D is linked to depressive symptoms in the general population. During pregnancy, your stores are shared with the fetus, and postpartum vitamin D insufficiency is common, particularly if you spent most of your pregnancy indoors or live at a northern latitude.
• B12 deficiency. Breastfeeding transfers B12 to your baby, and if your own stores were borderline during pregnancy, they can dip lower postpartum. Neurological symptoms and low mood are classic B12 deficiency findings.

How postpartum low mood is categorized: baby blues vs. PPD vs. Postpartum anxiety

These categories are not the same condition and they do not carry the same prognosis or treatment.

Baby blues

Baby blues affect up to 80% of women in the first week after delivery. Symptoms include tearfulness, irritability, mood swings, and feeling overwhelmed. They peak around day 3-5 and resolve completely by day 10-14. No medication is needed. What does help: rest, social support, and honest acknowledgment that your body just ran a neurochemical marathon. If symptoms have not improved by two weeks postpartum, that is the line that separates blues from something that warrants clinical evaluation.

Postpartum depression

Postpartum depression (PPD) affects approximately 1 in 7 women (about 14.5%), making it the most common complication of childbirth. Symptoms go beyond tearfulness: they include persistent low mood most of the day, loss of interest in activities you normally enjoy, difficulty bonding with your baby, significant sleep disruption beyond what newborn care explains, concentration problems, feelings of worthlessness or guilt, and in severe cases, thoughts of self-harm or harming the baby.

PPD can begin any time in the first year postpartum, not only in the first weeks.

Postpartum anxiety

Postpartum anxiety is at least as common as PPD and may be more prevalent in some populations, yet it is screened for less reliably. Symptoms include constant worry, intrusive thoughts about something bad happening to the baby, physical tension, racing heart, and difficulty sleeping even when the baby sleeps. The Edinburgh Postnatal Depression Scale does include an anxiety subscale, but dedicated tools like the Generalized Anxiety Disorder 7-item scale (GAD-7) may capture it better.

Postpartum psychosis

This is rare (1-2 per 1,000 deliveries) but a psychiatric emergency. Symptoms include hallucinations, delusions, rapid mood swings, confusion, and disorganized behavior, typically appearing within the first two weeks. Prior bipolar disorder or a personal or family history of postpartum psychosis are the strongest risk factors. This requires immediate emergency evaluation.

Which labs should you ask for?

A targeted lab panel can identify or rule out the medical causes of postpartum low mood within a few days. Ask your OB, midwife, or primary care provider for all of these at your postpartum visit, or sooner if your symptoms are affecting your ability to function.

| Lab | What it checks | Why it matters postpartum | |---|---|---| | TSH + free T4 | Thyroid function | Rules out postpartum thyroiditis (hyper or hypo phase) | | CBC with differential | Anemia, white cells | Detects iron-deficiency anemia from delivery blood loss | | Serum ferritin | Iron stores | More sensitive than hemoglobin alone; low stores worsen mood | | 25-OH Vitamin D | Vitamin D status | Deficiency common postpartum; correctable | | Vitamin B12 | B12 status | Depleted by breastfeeding in borderline-deficient women | | Fasting glucose or HbA1c | Blood sugar | New-onset type 2 or type 1 diabetes can debut postpartum | | Thyroid peroxidase antibodies (TPOAb) | Autoimmune thyroid risk | Predicts postpartum thyroiditis and future Hashimoto's | | Comprehensive metabolic panel | Liver, kidney, electrolytes | Baseline for medication decisions if treatment is needed |

This lab framework is a clinically grounded, systematically organized screening approach developed by the WomanRx editorial team to help postpartum women and their providers distinguish hormonal crash from treatable medical conditions, because no single published guideline currently consolidates all these checks into one postpartum mood panel.

The American College of Obstetricians and Gynecologists (ACOG) recommends thyroid screening if clinical symptoms suggest thyroid disease, but leaves the broader metabolic panel to clinical discretion. Asking for the full list above is a reasonable, evidence-based request.

Screening and diagnosis: how PPD is actually identified

No blood test diagnoses postpartum depression. Diagnosis is clinical, based on your symptoms, their duration, and a validated screening instrument.

The Edinburgh Postnatal Depression Scale

The EPDS is a 10-question self-report tool validated in postpartum women specifically. A score of 10 or above suggests possible depression and warrants further evaluation; a score of 13 or above is the standard cut-point for probable major depression. Question 10 screens directly for self-harm thoughts. ACOG recommends screening at least once during the perinatal period, and many practices now screen at the postpartum visit and again at the well-baby visits. Your pediatrician may administer the EPDS at your baby's 1- and 2-month appointments, which gives you an additional opportunity for early detection even if you do not have a postpartum appointment scheduled.

DSM-5 criteria for PPD

Clinically, PPD is classified under major depressive episode with peripartum onset in the DSM-5. Onset must occur during pregnancy or within four weeks of delivery by strict DSM-5 definition, but most clinicians and researchers extend this window to 12 months postpartum given the evidence that depression emerging later in the first year is biologically and clinically continuous with classic PPD.

Risk factors specific to women

Not every woman faces equal risk. Knowing your risk profile helps you and your provider prepare before delivery and monitor more closely afterward.

Factors that raise your risk include:

• Prior depression or anxiety. Women with a personal history of major depression have a 3-fold higher risk of postpartum depression.
• PMDD or severe PMS. Premenstrual dysphoric disorder indicates high neurobiological sensitivity to hormonal fluctuations, the same sensitivity that drives PPD.
• Prior PPD. The recurrence risk after a previous episode is approximately 41%, which is why proactive planning before the next delivery matters.
• Thyroid antibody positivity. TPOAb-positive women have a significantly higher rate of postpartum thyroiditis and related mood symptoms.
• PCOS. Women with polycystic ovary syndrome have higher baseline rates of depression and anxiety, and the postpartum hormonal environment may interact with their already-dysregulated androgen and insulin signaling.
• Preterm birth, NICU admission, or traumatic delivery. The psychological stress of a complicated birth adds to biological vulnerability.
• Lack of social support or intimate partner conflict. These are among the strongest non-biological predictors of PPD.
• History of trauma or adverse childhood experiences.

Who this is right for, and who needs a different approach

Postpartum low mood is not one-size-fits-all, and neither is the response.

Baby blues (0-2 weeks, resolving)

You need: reassurance, help at home, sleep in any quantity you can get, and a clear instruction to call your provider if symptoms are not improving by day 14. No medication is indicated.

Mild-to-moderate PPD or postpartum anxiety

You may benefit from psychotherapy, particularly cognitive behavioral therapy (CBT) or interpersonal therapy (IPT), which have strong evidence in postpartum depression. If you are breastfeeding, medication choices matter because drug transfer to breast milk varies. Sertraline (Zoloft) and paroxetine have the most published safety data in lactation and are generally considered first-line SSRIs for breastfeeding mothers. The LactMed database maintained by the NIH is the most current resource for checking individual drug safety during breastfeeding and is updated continuously.

Moderate-to-severe PPD

A combination of therapy and medication is typically more effective than either alone. If you have severe PPD that has not responded to two adequate SSRI trials, brexanolone (IV, 60-hour infusion, hospital-based) or zuranolone (Zurzuvae, an oral neuroactive steroid approved in 2023) may be appropriate. Zuranolone was approved by the FDA in August 2023 as the first oral medication specifically indicated for PPD, at a dose of 50 mg once daily for 14 days.

Postpartum thyroiditis with mood symptoms

If your TSH is abnormal, treating the thyroid dysfunction is the first step. The hypothyroid phase is treated with levothyroxine; the hyperthyroid phase is usually managed with beta-blockers for symptom relief (anti-thyroid drugs are not typically needed because this phase is transient). Most women recover normal thyroid function within 12-18 months, but 20-40% develop permanent hypothyroidism and require ongoing levothyroxine.

Iron or vitamin D deficiency

These are straightforward to treat. Oral iron supplementation (ferrous sulfate 325 mg once or twice daily with vitamin C to improve absorption) and vitamin D3 at doses guided by your lab result (commonly 2,000-4,000 IU daily for deficiency) are safe while breastfeeding. Recheck labs in 8-12 weeks.

Treatment options: what the evidence actually says

Psychotherapy

CBT and interpersonal therapy have the strongest evidence for PPD. A Cochrane review found psychological interventions significantly reduced depressive symptoms compared with usual care. Telehealth-delivered CBT shows comparable outcomes to in-person therapy, which matters when you cannot leave the house with a newborn.

SSRIs and SNRIs

Sertraline is the most studied SSRI in postpartum women and in lactation. The relative infant dose (RID) is typically below 1%, which is well under the 10% threshold considered acceptable during breastfeeding. Paroxetine has similarly low milk transfer. Fluoxetine has a longer half-life and higher RID and is generally a second-line choice for breastfeeding women. The ACOG practice bulletin on perinatal depression recommends SSRIs as first-line pharmacologic treatment when medication is indicated.

The clinician quote embedded in ACOG's 2023 guidelines states: "Untreated perinatal depression poses risks to both the mother and the infant, and these risks often outweigh the risks associated with pharmacologic treatment."

Neuroactive steroids (new category)

Zuranolone (Zurzuvae) 50 mg taken orally at bedtime for 14 days showed a significant reduction in HAMD-17 scores compared with placebo in the SKYLARK trial, with a mean difference of 4.2 points at day 15. The effect was rapid, with separation from placebo visible by day 3. Zuranolone is not recommended during breastfeeding due to insufficient human lactation data; discuss contraception and breastfeeding plans with your provider before starting.

Exercise

Structured aerobic exercise, at a minimum of 150 minutes per week, has demonstrated moderate antidepressant effects in postpartum women. A meta-analysis in the British Journal of General Practice found exercise reduced PPD scores significantly, with effect sizes comparable to mild-to-moderate antidepressant therapy. This is not a substitute for clinical treatment in moderate or severe PPD, but it is a meaningful adjunct and one you can start immediately.

Pregnancy and lactation: drug safety considerations

If you are breastfeeding, medication choices require careful consideration of drug transfer into breast milk.

Sertraline: Considered the preferred SSRI during lactation. Relative infant dose approximately 0.5-3%. No consistent adverse effects in breastfed infants reported in available studies. LactMed rating: generally compatible.

Paroxetine: Also considered compatible with breastfeeding; low milk transfer. Note: paroxetine carries a Pregnancy Category D label and is associated with neonatal adaptation syndrome if used in the third trimester. If you are planning a subsequent pregnancy, discuss this with your prescriber.

Fluoxetine: Longer half-life means higher accumulation in infant serum. Use with caution in breastfeeding, particularly in preterm infants or newborns. Not first-line for nursing mothers.

Zuranolone (Zurzuvae): No human lactation data available. The FDA label advises against use during breastfeeding. Women starting zuranolone should have a plan for either formula feeding or pumping and discarding for the treatment duration.

Brexanolone (Zulresso): Administered inpatient over 60 hours. No meaningful lactation data exists. Pumping and discarding during the infusion is typically advised.

Benzodiazepines (e.g., lorazepam for acute anxiety): Occasional short-term use may be acceptable, but regular use is discouraged during breastfeeding due to infant sedation risk. Discuss with your provider.

If you become pregnant again while on any psychiatric medication, do not stop abruptly. Work with your prescriber on a tapering or continuation plan based on your personal risk-benefit profile.

When to seek help urgently

Contact your provider the same day or go to an emergency department if you experience any of the following:

• Thoughts of harming yourself or ending your life
• Thoughts of harming your baby
• Inability to sleep for more than 24-48 hours even when your baby is cared for
• Seeing or hearing things others cannot (hallucinations)
• Feeling confused, disoriented, or unable to recognize familiar people
• Rapid escalation of symptoms over hours

These symptoms may indicate postpartum psychosis, which requires immediate psychiatric evaluation and is treatable with early intervention.

If you are having thoughts of self-harm right now, call or text 988 (Suicide and Crisis Lifeline) or go to your nearest emergency room.

Evidence gaps: what we do not yet know well enough

Women have been systematically under-represented in psychiatric drug trials. Most antidepressant efficacy data comes from mixed-sex trials, and PPD-specific trials typically include small samples. Here is what is directly studied vs. Extrapolated:

• Directly studied in postpartum women: EPDS validity, sertraline and paroxetine lactation data, brexanolone and zuranolone PPD-specific trials, CBT and IPT efficacy in PPD.
• Extrapolated from general adult data: Most SSRI dosing, long-term outcomes for postpartum anxiety treatment, optimal duration of antidepressant therapy after PPD resolution.
• Almost entirely unstudied: PPD in women with PCOS specifically, postpartum mood in gender-diverse individuals, and differential treatment response by hormonal profile.

This honesty matters because it means your provider's recommendations should be individualized, not templated.

Your concrete next steps

If you are postpartum and feeling persistently low, here is the practical sequence:

1. Complete an EPDS. You can find the validated scale on the ACOG website. Score yourself honestly. Share the result with your provider.
2. Book a visit within one week if your EPDS score is 10 or above, if your baby blues have not resolved by day 14, or if your mood is interfering with daily life or bonding.
3. Ask for the full lab panel listed in the table above, specifically TSH, free T4, TPOAb, CBC, ferritin, vitamin D, B12, and fasting glucose.
4. Tell your provider your full history, including prior depression, PMDD, or a previous episode of PPD. This changes risk stratification and treatment urgency.
5. If you are breastfeeding, say so clearly before any medication is prescribed, so the choice accounts for infant exposure.
6. Do not wait to feel better on your own beyond the two-week baby blues window. PPD does not reliably self-resolve, and the longer it goes untreated, the greater the impact on your bonding, your relationship, and your baby's developmental trajectory.

A TSH drawn at your six-week postpartum visit and repeated at four months is the single most actionable step to rule out postpartum thyroiditis before it is mistaken for PPD, because the two conditions can look nearly identical and they require completely different treatments.